Prescription Drug Reform
Expert articles and analysis related to prescription drug reform.
AI Summary — Last 7 Days
Synthesis:
In the past week, CMS finalized the 2027 Medicare Advantage and Part D payment policies, marking a larger-than-anticipated average rate increase of 2.48% and codifying Part D redesigns that are directly impacting plan payment structures and risk adjustment for VBC stakeholders. The finalized Part D risk adjustment updates—intentionally separating MA-PDs and PDPs—will shift plan incentives and payments for certain chronic conditions, while new programs like CMMI’s BALANCE, targeting GLP-1 therapy access for obesity, signal continued innovation in population health management frameworks. These changes underscore both escalating financial pressures and evolving accountability measures for ACOs, MA organizations, and plan sponsors navigating the next phase of Medicare prescription drug reform. Key sources: 2027 Part D Risk Adjustment Changes, [CMS Finalizes 2027 MA and Part D Payment Policies](https://news.google.com/rss/articles/CBMi9gFBVV95cUxOSHV6U0FnRERhNTVhclh2NFp3RHAwd0lGWGNfRWlMRDdZT2NLN2E2ZG9fUXZqbjhoTk5oLWN2QmNfM1FqNmNEbmcwVGt0T3FOZU10VWE1elNickprbnpZUTQ2
Related Articles
change its pharmacy care model
From newsletter: The LI Daily: Ascendiun CEO Paul Markovich wants the industry to back a policy reform movement focused on affordability, tech innovation Ascendiun CEO Paul Markovich wants the indus...
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Premier Responds to RFI on Potential 340B Rebate Model Pilot Program
Premier raised concerns that a rebate based approach to the 340B drug discount program would undermine the program and create significant risk for hospitals.
Standing up to Rising Prescription Drug Costs Increases Access to Breakthrough Medications
For millions of Americans, accessing the medications they need at prices they can afford has gotten increasingly difficult.
STAT+: Maryland state affordability board sets its first price cap for a medicine
The board will now oversee a process to lower the cost of the type 2 diabetes medicine Jardiance by January 2027.
CMS Proposes Reforms to Speed Patient Access to Drugs
CMS Proposes Reforms to Speed Patient Access to Drugs HCI Innovation Group
How health care lobbying distorts the U.S. opioid crisis
KevinMD recently published a paper describing the horrible impacts of health care lobbying in the U.S. This article assesses how effective the lobbyists have been in misdirecting four key legislators ...
In a first, a drugmaker’s lawsuit challenges HRSA’s 340B patient definition
In a new chapter for litigation involving the 340B Drug Pricing Program, a drugmaker is suing the federal government over the definition of patient as it pertains to the program. AbbVie Inc. says the ...
Recent 340B Court Rulings Sustain Blocked WV Law, Demand Decade-Old Federal Policy Be Set Aside
InsideHealthPolicy reports that a federal court ruled in favor of Premier Inc., vacating a decade-old HRSA policy limiting how certain 340B hospitals purchase drugs through group purchasing organizati...